Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Both the Antioxidant and D3 Agonist Actions of Pramipexole Mediate Its Neuroprotective Actions in Mesencephalic Cultures

Zao Dung Ling, Heather C. Robie, Chong Wai Tong and Paul M. Carvey
Journal of Pharmacology and Experimental Therapeutics April 1999, 289 (1) 202-210;
Zao Dung Ling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather C. Robie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chong Wai Tong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul M. Carvey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Pramipexole (PPX) is a full intrinsic activity, direct-acting dopamine (DA) agonist possessing 7-fold higher affinity for D3 than for D2 receptors. It also is a potent antioxidant. PPX was previously shown to be neuroprotective because it dose dependently attenuated the DA neuron loss produced by levodopa in mesencephalic cultures. Several different drugs with properties similar to PPX were studied here to better understand the mechanism or mechanisms responsible for this neuroprotective effect. The D3-preferring agonist 7-hydroxy-diphenylaminotetralin (7-OH-DPAT) and the D3 antagonist U99194, respectively, increased and decreased the neuroprotective effects of PPX in a dose-dependent fashion. Addition of the selective D2agonist U95666 or the D2/D3 antagonists domperidone or raclopride did not affect PPX’s neuroprotective effect. Interestingly, 7-OH-DPAT by itself did not attenuate the DA neuron loss produced by levodopa. However, when 7-OH-DPAT was combined with a low dose of the antioxidants U101033E or α-tocopherol, the toxic effects of levodopa were attenuated. Similar results were observed when the D3-preferring agonist PD128,907 was studied. In addition, media conditioned by exposure of mesencephalic cultures incubated with all D3-preferring agonists studied was shown to enhance the growth of DA neurons in freshly harvested recipient cultures implicating a D3-mediated trophic activity in the neuroprotective effect. These data suggest that PPX’s neuroprotective actions in the levodopa toxicity model are a consequence of its combined actions as a D3 receptor agonist and an antioxidant.

Footnotes

  • Send reprint requests to: Paul M. Carvey, Ph.D, Department of Pharmacology, Rush-Presbyterian-St. Luke’s Medical Center, 2242 West Harrison St., Suite 260, Chicago, IL 60612. E-mail:pcarvey{at}rush.edu

  • ↵1 This work was supported by National Institute of Neurological Disorders and Stroke Grant NS33174 and a grant from the Pharmacia and Upjohn Co.

  • Abbreviations:
    CM
    complete media
    DA
    dopamine
    DM
    defined media
    DMEM
    Dulbecco’s modified Eagle’s medium
    MPP+
    1-methyl-4-phenylpyridinium
    PC
    plate control
    7-OH-DPAT
    7-hydroxy-diphenylaminotetralin
    PD
    Parkinson’s disease
    PD128
    907, (+)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)-benzpyrano-(4,3b)-1,4-oxasin-9-ol
    PPX
    pramipexole
    RMT
    rostral mesencephalic tegmentum
    TH
    tyrosine hydroxylase
    THir
    TH immunoreactive
    U101033E
    pyrrolopyrimidine lipid peroxidation inhibitor (lazeroid compound)
    U95666
    (R)-5,6-diydro-5-(methylamino)-4H-imidazo-(4,5,1-ij)-quinolin-2(1H)-one monohydrochloride
    U99194
    5,6-dimethoxy-N,N-dipropyl-2-indanamine monochloride
    • Received June 24, 1998.
    • Accepted November 11, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 289 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 289, Issue 1
1 Apr 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Both the Antioxidant and D3 Agonist Actions of Pramipexole Mediate Its Neuroprotective Actions in Mesencephalic Cultures
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Both the Antioxidant and D3 Agonist Actions of Pramipexole Mediate Its Neuroprotective Actions in Mesencephalic Cultures

Zao Dung Ling, Heather C. Robie, Chong Wai Tong and Paul M. Carvey
Journal of Pharmacology and Experimental Therapeutics April 1, 1999, 289 (1) 202-210;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Both the Antioxidant and D3 Agonist Actions of Pramipexole Mediate Its Neuroprotective Actions in Mesencephalic Cultures

Zao Dung Ling, Heather C. Robie, Chong Wai Tong and Paul M. Carvey
Journal of Pharmacology and Experimental Therapeutics April 1, 1999, 289 (1) 202-210;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Activation of G Proteins by Neuropeptide Y and γ-Aminobutyric AcidB Receptor Agonists in Rat Cerebral Cortical Membranes through Distinct Modes of Action
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics